FDA and FTC warned Iotech International over ioRinse and ioCleanse marketed with unapproved COVID-19 prevention and treatment claims.
What happened
FDA and FTC reviewed Iotech International’s website and Facebook/Instagram pages in 2021 and 2022. The agencies found ioRinse and ioCleanse Molecular iodine Hand Cleanser sold with claims that they kill or inactivate coronavirus and help combat COVID-19. FDA said these are drugs and unapproved new drugs because no FDA-approved application is in effect.
What FDA found
The products were sold as drugs intended to prevent or treat COVID-19 without FDA approval.
section 505(a), FD&C Act, 21 U.S.C. § 355(a)The products are misbranded because they are nonprescription drugs that do not meet section 505G and lack an approved application.
section 502(ee), FD&C Act, 21 U.S.C. § 352(ee)The COVID-19 claims go beyond the antiseptic uses allowed in the tentative drug monographs, so the products do not qualify for marketing without approval under section 505G(a)(3).
section 505G(a)(3), FD&C Act, 21 U.S.C. § 355h(a)(3)ioCleanse labeling represents molecular iodine as an active ingredient that was not among the three Category III ingredients in the 1994 tentative final monograph for consumer antiseptic rubs.
1994 TFM, 59 FR 31402; 21 CFR 201.66(b)(2)The website, social media, and linked article claims misleadingly represent the products as safe or effective for COVID-19.
section 201(g)(1)(B)/(C), FD&C Act; 21 CFR 201.128FTC says the company lacked competent and reliable scientific evidence for claims that the products prevent, treat, or cure COVID-19.
FTC Act, 15 U.S.C. § 41 et seq.; COVID-19 Consumer Protection Act
What FDA wants
FDA asks the company to stop selling unapproved COVID-19 products immediately and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and documentation. FTC separately asks for certification within 48 hours that the unsubstantiated claims have ceased.
Who should pay attention
- companies selling antiseptic rinses or hand cleansers
- brands making COVID-19 claims in labeling or social media
- retailers and distributors of unapproved COVID-19 products
This is a summary. Read the original letter on fda.gov.